NCT01732445View on ClinicalTrials.gov

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 14, 2016

Study Completion Date

August 10, 2017

Conditions
AnemiaPrimary MyelofibrosisSecondary Myelofibrosis
Interventions
DRUG

ruxolitinib phosphate

Given PO

DRUG

danazol

Given PO

OTHER

quality-of-life assessment

Ancillary studies

OTHER

questionnaire administration

Ancillary studies

Trial Locations (2)

10029

Tisch Cancer Center, New York

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT01732445 - Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter